Info

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze (C1 inhibitor), is being developed as a replacement therapy both for the treatment and prevention of Hereditary Angioedema (HAE), also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. The company was founded in 2003 around a single premise: to bring C1 inhibitor, a treatment that has been used to manage HAE safely and effectively for more than 30 years in Europe, to the waiting patient population in the United States. In 2007, Lev met primary endpoints in its pivotal U.S. Phase III clinical trial for both the acute and prophylactic treatment of HAE, achieving clinical and statistical significance. Cinryze has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.